If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

Directorate Change

1 Feb 2010 12:50

RNS Number : 4556G
Minster Pharmaceuticals PLC
01 February 2010
 



 

 

For immediate release

1 February 2010

 

 

 

Minster Pharmaceuticals plc

("Minster" or the "Company")

 

 

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that further to the announcement made on 4 January 2010 regarding Peter Blower's intention to resign as a director of Minster on 31 January 2010, the Company has received notice of Mr Blower's resignation as a director with effect from 31 January 2010.

 

John Russell, Minster's Chairman, said: "We are grateful to Peter for his very significant contribution to Minster as an executive director over the last five years."

 

 

 

Enquiries

Minster Pharmaceuticals plc

Phone: +44 (0)20 7936 9921

John Russell, Chairman and Interim CEO

Karl Keegan, Chief Financial Officer

Buchanan Communications

Phone: +44 (0)20 7466 5000

Mark Court

Nomura Code Securities Limited

(Rule 3 Advisers & NOMAD)

Phone: +44 (0)20 7776 1200

Richard Potts, Giles Balleny

 

 

 

Dealing Disclosure Requirements

 

Under the provisions of the Rule 8.3 of the City Code, if any person is, or becomes, "interested" (directly or indirectly) in one per cent. or more of any class of "relevant securities" of Minster, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3:30 p.m. (London Time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Minster, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant securities" of Minster by Proximagen or Minster, or by any of their respective "associates", must be disclosed by no later than 12:00 noon (London Time) on the London business day following the date of the relevant transaction.

 

A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.

 

"Interest in securities" arises, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having as "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

 

Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADMGGZZMRGGZM
Date   Source Headline
27th Jun 20087:00 amRNSAHS Meeting
25th Jun 200810:28 amRNSDirector/PDMR Shareholding
24th Jun 200810:23 amRNSResult of Annual General Meet
24th Jun 20087:00 amRNSAGM Statement
16th Jun 20087:30 amRNSTEMPUS study fully enrolled
4th Jun 20087:00 amRNSAnnual Report and Accounts
2nd Jun 20087:00 amRNSUS Marketing Consultant
22nd May 20087:00 amRNSPreliminary Results
12th Mar 20087:00 amRNSAura trial fully enrolled
5th Feb 20087:00 amRNSTEMPUS Trial Update
3rd Dec 20077:00 amRNSInterim Results
16th Oct 20077:00 amRNSTEMPUS trial starts in US
4th Oct 200711:06 amRNSChange of Registered Office
28th Sep 200711:32 amRNSDirector/PDMR Shareholding
17th Aug 20077:00 amRNSAIM Rule 26
16th Jul 200711:29 amRNSResult of AGM
16th Jul 20077:00 amRNSAGM Statement
2nd Jul 20074:13 pmRNSHolding(s) in Company
27th Jun 20077:01 amRNSIHS Scientific Meeting
21st Jun 20075:05 pmRNSAnnual Report and Accounts
13th Jun 20077:02 amRNSPreliminary Results
7th Jun 20077:02 amRNSAHS Scientific Meeting
1st Jun 20078:30 amRNSTotal Voting Rights
18th May 20079:20 amRNSAdditional Listing
30th Apr 20076:22 pmRNSHolding(s) in Company
30th Apr 200712:16 pmRNSTotal Voting Rights
11th Apr 20074:39 pmRNSConversion of Loan Note
2nd Apr 20073:27 pmRNSHolding(s) in Company
2nd Apr 20072:55 pmRNSHolding(s) in Company
2nd Apr 20071:26 pmRNSDirector/PDMR Shareholding
30th Mar 20079:32 amRNSTotal Voting Rights
27th Mar 20077:01 amRNSBoard Appointments
26th Mar 200710:31 amRNSResult of EGM
2nd Mar 20077:30 amRNSGPB17m fundraising
9th Jan 20077:01 amRNSPositive Tonabersat Study
20th Dec 20065:43 pmRNSTotal Voting Rights
1st Dec 20067:01 amRNSInterim Results
17th Nov 20067:01 amRNSPlacing
25th Oct 200610:20 amRNSResult of AGM
25th Oct 20067:01 amRNSAGM Statement
27th Sep 20067:00 amRNSNIH Collaboration
20th Sep 20067:02 amRNSPreliminary Results
7th Sep 20067:00 amRNSAdditional Indications
15th Aug 200611:37 amRNSNotification of Interests
20th Jun 20067:00 amRNSStart of Phase II Trial
24th May 20067:01 amRNSUCLA Collaboration
21st Mar 20067:00 amRNSStart of Phase II Trial
8th Mar 20067:03 amRNSChange of Adviser
13th Jan 20067:00 amPRNRe Agreement
8th Dec 20057:00 amPRNInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.